Literature DB >> 29140556

WITHDRAWN: Transcendental meditation for the primary prevention of cardiovascular disease.

Louise Hartley1, Angelique Mavrodaris, Nadine Flowers, Edzard Ernst, Karen Rees.   

Abstract

BACKGROUND: A major determinant in cardiovascular disease (CVD) is stress. As transcendental meditation (TM) is thought to help in lowering negative stress indicators, it may be a beneficial strategy for the primary prevention of CVD.
OBJECTIVES: To determine the effectiveness of TM for the primary prevention of CVD. SEARCH
METHODS: We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 10); MEDLINE (Ovid) (1946 to week three November 2013); EMBASE Classic and EMBASE (Ovid) (1947 to week 48 2013); ISI Web of Science (1970 to 28 November 2013); and Database of Abstracts of Reviews of Effects (DARE) and Health Technology Assessment Database and Health Economics Evaluations Database (November 2013). We also searched the Allied and complementary Medicine Database (AMED) (inception to January 2014) and IndMed (inception to January 2014). We handsearched trial registers and reference lists of reviews and articles and contacted experts in the field. We applied no language restrictions. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of at least three months' duration involving healthy adults or adults at high risk of CVD. Trials examined TM only and the comparison group was no intervention or minimal intervention. We excluded trials that involved multi-factorial interventions. Outcomes of interest were clinical CVD events (cardiovascular mortality, all-cause mortality and non-fatal events) and major CVD risk factors (e.g. blood pressure and blood lipids, occurrence of type 2 diabetes, quality of life, adverse events and costs). DATA COLLECTION AND ANALYSIS: Two authors independently selected trials for inclusion, extracted data and assessed the risk of bias. MAIN
RESULTS: We identified four trials (four papers) (430 participants) for inclusion in this review. We identified no ongoing studies. The included trials were small, short term (three months) and at risk of bias. In all studies, TM was practised for 15 to 20 minutes twice a day.None of the included studies reported all-cause mortality, cardiovascular mortality or non-fatal endpoints as trials were short term, but one study reported survival rate three years after the trial was completed. In view of the considerable statistical heterogeneity between the results of the studies for the only outcomes reported, systolic blood pressure (I2 = 72%) and diastolic blood pressure (I2 = 66%), we decided not to undertake a meta-analysis. None of the four trials reported blood lipids, occurrence of type 2 diabetes, adverse events, costs or quality of life. AUTHORS'
CONCLUSIONS: Currently, there are few trials with limited outcomes examining the effectiveness of TM for the primary prevention of CVD. Due to the limited evidence to date, we could draw no conclusions as to the effectiveness of TM for the primary prevention of CVD. There was considerable heterogeneity between trials and the included studies were small, short term and at overall serious risk of bias. More and larger long-term, high-quality trials are needed.

Entities:  

Mesh:

Year:  2017        PMID: 29140556      PMCID: PMC6486000          DOI: 10.1002/14651858.CD010359.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  34 in total

1.  Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature.

Authors:  J A Sterne; D Gavaghan; M Egger
Journal:  J Clin Epidemiol       Date:  2000-11       Impact factor: 6.437

Review 2.  Mind-body medicine. An introduction and review of the literature.

Authors:  Kevin A Barrows; Bradly P Jacobs
Journal:  Med Clin North Am       Date:  2002-01       Impact factor: 5.456

Review 3.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis.

Authors:  J A Sterne; M Egger; G D Smith
Journal:  BMJ       Date:  2001-07-14

Review 4.  Review of controlled research on the transcendental meditation program and cardiovascular disease. Risk factors, morbidity, and mortality.

Authors:  Kenneth G Walton; Robert H Schneider; Sanford Nidich
Journal:  Cardiol Rev       Date:  2004 Sep-Oct       Impact factor: 2.644

5.  Impact of transcendental meditation on ambulatory blood pressure in African-American adolescents.

Authors:  Vernon A Barnes; Frank A Treiber; Maribeth H Johnson
Journal:  Am J Hypertens       Date:  2004-04       Impact factor: 2.689

6.  Effect of a multimodality natural medicine program on carotid atherosclerosis in older subjects: a pilot trial of Maharishi Vedic Medicine.

Authors:  Jeremy Z Fields; Kenneth G Walton; Robert H Schneider; Sanford Nidich; Rhoda Pomerantz; Parmi Suchdev; Amparo Castillo-Richmond; Kathleen Payne; Elizabeth T Clark; Maxwell Rainforth
Journal:  Am J Cardiol       Date:  2002-04-15       Impact factor: 2.778

Review 7.  Psychosocial stress and cardiovascular disease: pathophysiological links.

Authors:  C Noel Bairey Merz; James Dwyer; Cheryl K Nordstrom; Kenneth G Walton; John W Salerno; Robert H Schneider
Journal:  Behav Med       Date:  2002       Impact factor: 3.104

8.  Acute effects of transcendental meditation on hemodynamic functioning in middle-aged adults.

Authors:  V A Barnes; F A Treiber; J R Turner; H Davis; W B Strong
Journal:  Psychosom Med       Date:  1999 Jul-Aug       Impact factor: 4.312

Review 9.  The cumulative effects of Transcendental Meditation on cognitive function--a systematic review of randomised controlled trials.

Authors:  Peter H Canter; Edzard Ernst
Journal:  Wien Klin Wochenschr       Date:  2003-11-28       Impact factor: 2.275

10.  Effects of stress reduction on carotid atherosclerosis in hypertensive African Americans.

Authors:  A Castillo-Richmond; R H Schneider; C N Alexander; R Cook; H Myers; S Nidich; C Haney; M Rainforth; J Salerno
Journal:  Stroke       Date:  2000-03       Impact factor: 10.170

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.